Interim Buprenorphine Treatment During Delays to Comprehensive Treatment: Changes in Psychiatric Symptoms

Overview

Journal Exp Clin Psychopharmacol

Publisher American Psychological Association

Specialty Pharmacology

Date 2018 Jun 26

PMID 29939049

Citations 15

Authors

Joanna M Streck

Taylor A Ochalek

Gary J Badger

Stacey C Sigmon

Affiliations

Soon will be listed here.

Abstract

Prevalence of depression, anxiety, and mood disorders among individuals with opioid use disorder far exceeds that of the general population. While psychiatric symptoms often improve upon entry into opioid treatment, this has typically been seen with treatments involving psychosocial counseling. In this secondary analysis, we examined changes in psychiatric symptoms during a randomized clinical trial evaluating an interim buprenorphine treatment without counseling among individuals awaiting entry into comprehensive treatment. Waitlisted adults with opioid use disorder ( = 50) were randomized to one of two 12-week conditions: interim buprenorphine treatment (IBT; = 25) consisting of buprenorphine maintenance using a computerized medication dispenser, with bimonthly clinic visits and technology-assisted monitoring, or waitlist control (WLC; = 25), wherein participants remained on the waitlist of their local clinic. All participants completed assessments of psychiatric symptoms at intake and Study Weeks 4, 8, and 12. We examined changes on the Beck Anxiety Inventory (BAI), Beck Depression Inventory-II (BDI-II), Brief Symptom Inventory (BSI), and Psychiatric subscale of the Addiction Severity Index (ASI). Significant group-by-time interactions were observed for all measures of psychiatric severity examined: BAI ( < .05), BDI-II ( < .01), 5 BSI subscales (s < .05), and the ASI Psychiatric subscale ( < .05). On all measures, IBT participants reported significantly reduced psychiatric severity at the 4-, 8-, and 12-week assessments relative to baseline. In contrast, there were no significant changes in psychiatric symptoms among WLC participants. IBT without counseling may improve psychiatric distress among waitlisted individuals with opioid use disorder. (PsycINFO Database Record

Citing Articles

A novel prolonged exposure therapy protocol for improving therapy session attendance and PTSD symptoms among adults receiving buprenorphine or methadone treatment.

Peck K, Giannini J, Badger G, Cole R, Sigmon S Drug Alcohol Depend. 2024; 266:112507.

PMID: 39642783 PMC: 11685033. DOI: 10.1016/j.drugalcdep.2024.112507.

Prolonged exposure therapy for PTSD in individuals with opioid use disorder: A randomized pilot study.

Peck K, Badger G, Cole R, Higgins S, Moxley-Kelly N, Sigmon S Addict Behav. 2023; 143:107688.

PMID: 36989699 PMC: 10291821. DOI: 10.1016/j.addbeh.2023.107688.

Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Nielsen S, Tse W, Larance B Cochrane Database Syst Rev. 2022; 9:CD011117.

PMID: 36063082 PMC: 9443668. DOI: 10.1002/14651858.CD011117.pub3.

National Trends in Suicide Thoughts and Behavior among US Adults with Opioid Use Disorder from 2015 to 2020.

Streck J, Parker M, Bearnot B, Kalagher K, Sigmon S, Goodwin R Subst Use Misuse. 2022; 57(6):876-885.

PMID: 35232317 PMC: 9084338. DOI: 10.1080/10826084.2022.2046102.

Interim opioid agonist treatment for opioid addiction: a systematic review.

Jofra L, Puig T, Sola I, Trujols J Harm Reduct J. 2022; 19(1):7.

PMID: 35090475 PMC: 8800211. DOI: 10.1186/s12954-022-00592-x.

References

Clark H . A new era in opioid dependency treatment. Recent law allows qualified physicians to provide care in office setting. Postgrad Med. 2001; 109(6):15-6, 25. DOI: 10.3810/pgm.2001.06.964. View

Hser Y, Hoffman V, Grella C, Anglin M . A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001; 58(5):503-8. DOI: 10.1001/archpsyc.58.5.503. View

Gonzalez-Saiz F, Lozano Rojas O, Martin Esteban J, Bilbao Acedos I, Ballesta Gomez R, Gutierrez Ortega J . Psychiatric comorbidity in a sample of opiate-dependent patients treated with sublingual buprenorphine in a therapeutic community regime. Rev Psiquiatr Salud Ment. 2013; 4(2):81-7. DOI: 10.1016/j.rpsm.2011.01.003. View

Nunes E, Sullivan M, Levin F . Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004; 56(10):793-802. DOI: 10.1016/j.biopsych.2004.06.037. View

Kidorf M, Disney E, King V, Neufeld K, Beilenson P, Brooner R . Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004; 74(2):115-22. DOI: 10.1016/j.drugalcdep.2003.11.014. View

Strain E . Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002; 18(4 Suppl):S14-27. DOI: 10.1097/00002508-200207001-00003. View

Marsch L . The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998; 93(4):515-32. DOI: 10.1046/j.1360-0443.1998.9345157.x. View

Krook A, Brors O, Dahlberg J, Grouff K, Magnus P, Roysamb E . A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002; 97(5):533-42. DOI: 10.1046/j.1360-0443.2002.00090.x. View

Carpentier P, Krabbe P, van Gogh M, Knapen L, Buitelaar J, de Jong C . Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009; 18(6):470-80. DOI: 10.3109/10550490903205652. View

10.

Clausen T, Waal H, Thoresen M, Gossop M . Mortality among opiate users: opioid maintenance therapy, age and causes of death. Addiction. 2009; 104(8):1356-62. DOI: 10.1111/j.1360-0443.2009.02570.x. View

11.

McLellan A, Kushner H, Metzger D, Peters R, Smith I, Grissom G . The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992; 9(3):199-213. DOI: 10.1016/0740-5472(92)90062-s. View

12.

Drymalski W, Nunley M . The Use of the Addiction Severity Index Psychiatric Composite Scores to Predict Psychiatric Inpatient Admissions. J Addict Nurs. 2016; 27(3):190-6. DOI: 10.1097/JAN.0000000000000134. View

13.

Stotts A, Dodrill C, Kosten T . Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother. 2009; 10(11):1727-40. PMC: 2874458. DOI: 10.1517/14656560903037168. View

14.

Karp J, Butters M, Begley A, Miller M, Lenze E, Blumberger D . Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014; 75(8):e785-93. PMC: 4157317. DOI: 10.4088/JCP.13m08725. View

15.

Johnson R, Strain E, Amass L . Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(2 Suppl):S59-77. DOI: 10.1016/s0376-8716(03)00060-7. View

16.

Griffin M, Dodd D, Potter J, Rice L, Dickinson W, Sparenborg S . Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder. Am J Drug Alcohol Abuse. 2013; 40(2):157-62. PMC: 3947491. DOI: 10.3109/00952990.2013.842241. View

17.

Kessler R, Chiu W, Demler O, Merikangas K, Walters E . Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617-27. PMC: 2847357. DOI: 10.1001/archpsyc.62.6.617. View

18.

Mattick R, Breen C, Kimber J, Davoli M . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003; (4):CD002209. DOI: 10.1002/14651858.CD002209. View

19.

Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A . Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res. 2009; 166(1):7-14. DOI: 10.1016/j.psychres.2007.12.007. View

20.

Kabacoff R, Segal D, Hersen M, Van Hasselt V . Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. J Anxiety Disord. 1997; 11(1):33-47. DOI: 10.1016/s0887-6185(96)00033-3. View